SOLENO

Soleno is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases... At Soleno, we are researching and developing medicines to treat rare genetic disorders, beginning with Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive and behavioral difficulties. Our priority is to bring the first approved treatment to patients to manage the most burdensome aspects of this devastating disorder... Soleno is committed to maximizing shareholder value by developing and commercializing safe and effective therapeutic products that improve the lives of patients living with complex, life-threatening rare diseases with unmet medical needs.

Also known as: Soleno Therapeutics, Soleno Therapeutics Inc.

Primary location: Redwood City United States